This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Patients who are diagnosed with relapsed/refractory B cell non-Hodgkin lymphoma , especially
Diffuse Large B Cell Lymphoma, not other specified (DLBCL,NOS),
Primary Mediastinal Large B Cell Lymphoma (PMBCL)
Transformation Follicular Lymphoma (TFL)
Individuals who have antiCD45 or antiCD3 therapy
Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of primary or secondary CNS (central nervous system) lymphoma, cerebrospinal fluid malignant cells or brain metastases
Presence or history of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
History of allogeneic stem cell transplantation